Phytopharm announced the results of the Phase II, randomised,
double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated
patients with early-stage Parkinson’s Disease. Cogane was found to have no
beneficial effects at all on Parkinson's Disease symptoms.
Cogane, which
can be taken orally, readily crosses the blood-brain barrier and has been shown
to stimulate the release of GDNF. GDNF can indirectly stimulate the formation of
dopamine, the substance whose insufficiency causes Parkinson's Disease.
However, GDNF deficiency has never been shown to be the cause of Parkinson's
Disease. Previous studies claiming efficacy for Cogane in Parkinson's Disease
were only carried out in Macaque monkeys who did not actually have Parkinson's
Disease.
No comments:
Post a Comment